Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Breast Cancer
Open-data reference.
10 US clinical trials · 6 currently recruiting
Active & Recent Trials
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT07085767
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
BioNTech SE
NCT06827236
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals
NCT05508906
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT06727773
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06246968
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Alison Stopeck
NCT06220214
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT03255577
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
BioNTech SE
NCT06449222
Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT05383196
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT03685331
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 6 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Locally Advanced Breast Cancer Trial Landscape
ClinicalTrials.gov lists 10 US studies indexed under Locally Advanced Breast Cancer, and 6 of those are currently open to recruitment — roughly 60% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Locally Advanced Breast Cancer shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 8 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Locally Advanced Breast Cancer is led by Olema Pharmaceuticals with 2 indexed trials, alongside 6 other organizations in the top contributor list. The list on this page surfaces up to 10 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Locally Advanced Breast Cancer?
PlainTrial tracks 10 US clinical trials for Locally Advanced Breast Cancer, of which 6 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Locally Advanced Breast Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.